G. Kenneth Lloyd

4.4k total citations
80 papers, 3.1k citations indexed

About

G. Kenneth Lloyd is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, G. Kenneth Lloyd has authored 80 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 18 papers in Oncology and 16 papers in Cellular and Molecular Neuroscience. Recurrent topics in G. Kenneth Lloyd's work include Nicotinic Acetylcholine Receptors Study (24 papers), Ubiquitin and proteasome pathways (21 papers) and Cholinesterase and Neurodegenerative Diseases (12 papers). G. Kenneth Lloyd is often cited by papers focused on Nicotinic Acetylcholine Receptors Study (24 papers), Ubiquitin and proteasome pathways (21 papers) and Cholinesterase and Neurodegenerative Diseases (12 papers). G. Kenneth Lloyd collaborates with scholars based in United States, Australia and Switzerland. G. Kenneth Lloyd's co-authors include Michael Williams, Frédérique Menzaghi, Michael A. Palladino, Tadimeti S. Rao, Saskia Neuteboom, Barbara C. M. Potts, Aida Sacaan, Kin S. Lam, Jay S. Schneider and Julia Dunlop and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

In The Last Decade

G. Kenneth Lloyd

79 papers receiving 3.0k citations

Peers

Countries citing papers authored by G. Kenneth Lloyd

Since Specialization

Citations

This map shows the geographic impact of G. Kenneth Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Kenneth Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Kenneth Lloyd more than expected).

Fields of papers citing papers by G. Kenneth Lloyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Kenneth Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Kenneth Lloyd. The network helps show where G. Kenneth Lloyd may publish in the future.

Co-authorship network of co-authors of G. Kenneth Lloyd

This figure shows the co-authorship network connecting the top 25 collaborators of G. Kenneth Lloyd. A scholar is included among the top collaborators of G. Kenneth Lloyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Kenneth Lloyd. G. Kenneth Lloyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies 2019 ·Cancer Chemotherapy and Pharmacology ·James R. Tonra, G. Kenneth Lloyd, Ramon Mohanlal, Lan Huang	24
2	Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier 2015 ·Neuro-Oncology ·Kaijun Di, G. Kenneth Lloyd, (unknown), Ann MacLaren, Francis Burrows, Annick Desjardins, Mohit Trikha, Daniela A. Bota	107
3	Synthesis and structure–activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents 2012 ·Bioorganic & Medicinal Chemistry ·Yuri Yamazaki, (unknown), (unknown), Yoshiki Hayashi, Hiroyuki Yasui, Yoshiaki Kiso, Takumi Chinen, Takeo Usui, Fumika Yakushiji, Barbara C. M. Potts, Saskia Neuteboom, Michael A. Palladino, G. Kenneth Lloyd, Yoshio Hayashi	41
4	Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation 2011 ·International Journal of Radiation Biology ·Lotte Bonde Bertelsen, Yuan Shen, Thomas Nielsen, Hans Stødkilde‐Jørgensen, G. Kenneth Lloyd, Dietmar W. Siemann, Michael R. Horsman	24
5	Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Amanda Obaidat, Jeffrey Weiss, (unknown), Rama Rao Manam, Venkat R. Macherla, Katherine McArthur, Ta‐Hsiang Chao, Michael A. Palladino, G. Kenneth Lloyd, Barbara C. M. Potts, S.J. Enna, Saskia Neuteboom, Bruno Hagenbuch	25
6	Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel 2011 ·Investigational New Drugs ·Michael Millward, Paul N. Mainwaring, Alain C. Mita, (unknown), G. Kenneth Lloyd, (unknown), Steffan T. Nawrocki, Monica Mita, Matthew A. Spear	66
7	Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model 2010 ·British Journal of Haematology ·Ajita Singh, Michael A. Palladino, G. Kenneth Lloyd, Barbara C. M. Potts, Dharminder Chauhan, Kenneth C. Anderson	51
8	Tubulin Photoaffinity Labeling with Biotin‐Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents 2008 ·ChemBioChem ·Yuri Yamazaki, Kyoko Kohno, Hiroyuki Yasui, Yoshiaki Kiso, Miki Akamatsu, Benjamin Nicholson, Gordafaried Deyanat‐Yazdi, Saskia Neuteboom, Barbara C. M. Potts, G. Kenneth Lloyd, Yoshio Hayashi	13
9	Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas 2007 ·Molecular Cancer Therapeutics ·Patricia LoRusso, Lorrin Yee, K. Papadopoulos, (unknown), (unknown), (unknown), Elisabeth I. Heath, G. Kenneth Lloyd, (unknown), Saskia Neuteboom, (unknown), G. Cropp, Matthew A. Spear, Monica Mita	1
10	Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib) 2006 ·Cancer Research ·Ta‐Hsiang Chao, Dharminder Chauhan, Gordafaried Deyanat‐Yazdi, Laurence Catley, Paul G. Richardson, G. Kenneth Lloyd, Saskia Neuteboom, Kenneth C. Anderson, Michael A. Palladino	1
11	SIB-1553A, (±)-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Bruno Bontempi, Kevin Whelan, Victoria B. Risbrough, Tadimeti S. Rao, Jerry J. Buccafusco, G. Kenneth Lloyd, Frédérique Menzaghi	49
12	Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization 2000 ·The Journal of Comparative Neurology ·Maryka Quik, (unknown), Alison Gillespie, Michael W. Jakowec, G. Kenneth Lloyd, J. William Langston	148
13	Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression 2000 ·Psychopharmacology ·Susan M. Ferguson, Jesse Brodkin, G. Kenneth Lloyd, Frédérique Menzaghi	72
14	The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents 1998 ·Life Sciences ·G. Kenneth Lloyd, Frédérique Menzaghi, Bruno Bontempi, Carla M. Suto, Robert D. Siegel, M. Akong, Kenneth A. Stauderman, Gönül Veliçelebi, Edwin C. Johnson, Michael M. Harpold, Tadimeti S. Rao, Aida Sacaan, Laura E. Chavez-Noriega, Mark Washburn, (unknown), Nicholas D. P. Cosford, Leonard A. McDonald	51
15	Conformationally restricted analogues of nicotine and anabasine 1998 ·Bioorganic & Medicinal Chemistry Letters ·Jean‐Michel Vernier, (unknown), Nicholas D. P. Cosford, Jeffrey P. Whitten, Frédérique Menzaghi, Richard T. Reid, Tadimeti S. Rao, Aida Sacaan, G. Kenneth Lloyd, Carla M. Suto, Laura E. Chavez-Noriega, Mark Washburn, Arturo Urrutia, Ian A. McDonald	34
16	Effects of the nicotinic acetylcholine receptor agonist SIB‐1508Y on object retrieval performance in MPTP‐Treated monkeys: Comparison with levodopa treatment 1998 ·Annals of Neurology ·Jay S. Schneider, (unknown), Frédérique Menzaghi, G. Kenneth Lloyd	50
17	6-hydroxydopamine lesion of rat nigrostriatal dopaminergic neurons differentially affects nicotinic acetylcholine receptor subunit mRNA expression 1998 ·Journal of Molecular Neuroscience ·Kathryn Elliott, Jay M. Jones, Aida Sacaan, G. Kenneth Lloyd, (unknown)	31
18	Effects of a Novel Cholinergic Ion Channel Agonist SIB-1765F on Locomotor Activity in Rats 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Frédérique Menzaghi, Kevin Whelan, Victoria B. Risbrough, Tadimeti S. Rao, G. Kenneth Lloyd	40
19	Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·Aida Sacaan, Julia Dunlop, G. Kenneth Lloyd	114
20	GAEAA receptor complex function in frontal cortex membranes from control and neurological patients 1991 ·European Journal of Pharmacology ·G. Kenneth Lloyd, Armand Löwenthal, France Javoy‐Agid, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact